Lockdown of Breast Cancer Screening for COVID-19: Possible Scenario.

Szczegóły
Abstrakt

Tytuł:: Lockdown of Breast Cancer Screening for COVID-19: Possible Scenario.
Autorzy:: Vanni G; Breast Unit, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Pellicciaro M; Breast Unit, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy .
Materazzo M; Breast Unit, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Bruno V; Section of Gynecology, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Oldani C; Department of Economics and Engineering, University of Viterbo 'La Tuscia', Viterbo, Italy.
Pistolese CA; Department of Diagnostic Imaging and Interventional Radiology, Molecular Imaging and Radiotherapy Policlinico Tor Vergata University, Rome, Italy.
Buonomo C; Department of Emergency and Admission, Critical Care Medicine, Pain Medicine and Anesthetic Science, Policlinico Tor Vergata University, Rome, Italy.
Caspi J; Breast Unit, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Gualtieri P; Department of Biomedicine and Prevention, Policlinico Tor Vergata University, Rome, Italy.
Chiaravalloti A; Department of Biomedicine and Prevention, Policlinico Tor Vergata University, Rome, Italy.; IRCCS Neuromed, UOC Medicina Nucleare, Pozzilli, Italy.
Palombi L; Department of Biomedicine and Prevention, Policlinico Tor Vergata University, Rome, Italy.
Piccione E; Section of Gynecology, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Buonomo OC; Breast Unit, Department of Surgical Science, Policlinico Tor Vergata University, Rome, Italy.
Źródło:: In vivo (Athens, Greece) [In Vivo] 2020 Sep-Oct; Vol. 34 (5), pp. 3047-3053.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: <2000- > : Attiki, Greece : International Institute of Anticancer Research
Original Publication: Athens : Dr. J.G. Delinassios
MeSH Terms:: Early Detection of Cancer*
Breast Neoplasms/*diagnosis
Coronavirus Infections/*epidemiology
Mass Screening/*trends
Pneumonia, Viral/*epidemiology
Aged ; Betacoronavirus/pathogenicity ; Breast Neoplasms/complications ; Breast Neoplasms/epidemiology ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/virology ; Female ; Humans ; Mammography ; Middle Aged ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/virology ; SARS-CoV-2
References:: Int J Mol Sci. 2017 Jul 07;18(7):. (PMID: 28686211)
In Vivo. 2019 Nov-Dec;33(6):1879-1884. (PMID: 31662515)
N Engl J Med. 2020 Apr 30;382(18):1677-1679. (PMID: 32109012)
Cancer Radiother. 2015 Aug;19(5):295-302. (PMID: 26188735)
Int J Breast Cancer. 2014;2014:469803. (PMID: 24672730)
Clin Breast Cancer. 2014 Aug;14(4):235-40. (PMID: 24703317)
Ann Surg Oncol. 2018 Oct;25(10):2829-2838. (PMID: 29968031)
Anticancer Res. 2001 May-Jun;21(3C):2091-7. (PMID: 11501831)
Cancer. 2013 Jun 1;119(11):2022-8. (PMID: 23504860)
N Engl J Med. 2015 Apr 9;372(15):1381-4. (PMID: 25853741)
World J Surg. 2019 Mar;43(3):839-845. (PMID: 30456482)
Cell Biochem Biophys. 2015 Jun;72(2):333-8. (PMID: 25543329)
Eur J Breast Health. 2020 Mar 25;16(2):86-88. (PMID: 32285027)
Breast. 2013 Apr;22(2):101-108. (PMID: 23422255)
J Med Screen. 2012;19 Suppl 1:5-13. (PMID: 22972806)
Front Oncol. 2020 May 22;10:938. (PMID: 32574281)
Eur Radiol. 2017 Jul;27(7):2737-2743. (PMID: 27807699)
Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1341-1345. (PMID: 28387892)
Breast Cancer Res. 2011;13(6):R134. (PMID: 22204661)
In Vivo. 2020 Jun;34(3 Suppl):1651-1659. (PMID: 32503825)
In Vivo. 2020 Jun;34(3 Suppl):1661-1665. (PMID: 32503826)
Zhonghua Zhong Liu Za Zhi. 2020 Apr 23;42(4):288-291. (PMID: 32100979)
Int J Med Inform. 2018 Feb;110:1-9. (PMID: 29331247)
Eur J Cancer. 2017 Apr;75:109-116. (PMID: 28222306)
Int J Biol Sci. 2017 Nov 1;13(11):1387-1397. (PMID: 29209143)
Radiology. 2015 Dec;277(3):663-84. (PMID: 26599926)
Int J Cancer. 2019 Apr 15;144(8):1941-1953. (PMID: 30350310)
Zhonghua Wai Ke Za Zhi. 2020 May 1;58(5):331-336. (PMID: 32096395)
PLoS One. 2019 Dec 16;14(12):e0226352. (PMID: 31841563)
Insights Imaging. 2012 Feb;3(1):7-10. (PMID: 22695994)
N Engl J Med. 2015 Jun 11;372(24):2353-8. (PMID: 26039523)
Clin Radiol. 1996 Apr;51(4):277-81. (PMID: 8617041)
Eur Rev Med Pharmacol Sci. 2016 Jul;20(14):2950-4. (PMID: 27460720)
J Mech Behav Biomed Mater. 2018 Feb;78:420-426. (PMID: 29223730)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
In Vivo. 2017 01-02;31(1):101-110. (PMID: 28064227)
N Engl J Med. 2005 Oct 27;353(17):1784-92. (PMID: 16251534)
Tumori. 2002 May-Jun;88(3):S48-9. (PMID: 12365390)
Cancer. 1994 Mar 15;73(6):1666-72. (PMID: 8156494)
Cancer Sci. 2011 Mar;102(3):509-15. (PMID: 21175994)
Contributed Indexing:: Keywords: COVID-19; SARS-SOV-2; breast cancer; breast cancer screening; early diagnosis; local advanced diagnosis; mammography
Entry Date(s):: Date Created: 20200903 Date Completed: 20200907 Latest Revision: 20201218
Update Code:: 20240104
PubMed Central ID:: PMC7652450
DOI:: 10.21873/invivo.12139
PMID:: 32871851
: Czasopismo naukowe

Background/aim: Coronavirus disease is spreading worldwide. Due to fast transmission and high fatality rate drastic emergency restrictions were issued. During the lockdown, only urgent medical services are guaranteed. All non-urgent services, as breast cancer (BC) screening, are temporarily suspended. The potential of breast cancer screening programs in increasing the survival rate and decreasing the mortality rate has been widely confirmed. Suspension could lead to worse outcomes for breast cancer patients. Our study aimed to analyse the data and provide estimates regarding the temporary BC screening suspension.
Patients and Methods: Data regarding breast cancer and respective screening programs were achieved through literature research and analysis.
Results: Considering three different scenarios with respect to the lockdown's impact on breast cancer screening, we estimate that approximately 10,000 patients could have a missed diagnosis during these 3 months. Considering a 6-month period, as suggested by the Imperial college model, the number of patients who will not receive a diagnosis will rise to 16,000.
Conclusion: Breast cancer screening should be resumed as soon as possible in order to avoid further breast cancer missed diagnosis and reduce the impact of delayed diagnosis.
(Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Informacja